Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: Acute and 3-month effects on biomarkers of bone turnover
Tanko, L. B.; Bagger, Y. Z.; Alexandersen, P.et al.
2004 • In Journal of Bone and Mineral Research, 19 (9), p. 1531-1538
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women Acute and 3-month effects on biomarkers of bone turnover.pdf
[en] Oral administration of calcitonin could improve compliance to long-term treatment. Efficacy and safety of a novel oral formulation was assessed on 277 postmenopausal women. The results show (1) effective enteral absorption, (2) marked inhibition of bone resorption with minimal alteration of formation, and (3) reproducibility of responses over 3 months. Introduction: We have recently introduced an Eligen technology-based oral formulation of salmon calcitonin (sCT) that effectively delivers the hormone to the circulation. The efficacy and safety during longer-term administration, however. has not been investigated in the target population. Materials and Methods: This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging clinical trial including 277 healthy postmenopausal women 55-85 years of age. Women received treatment with either daily (0.15, 0.4. 1.0, or 2.5 mg) or intermittent doses (1.0 mg, every other day) of sCT combined with the delivery agent (8-[N-2-hydroxi-5-chloro-benzoyl]-amino-caprylic acid, 200 mg) or placebo for 3 months. All participants received 1000 mg calcium plus 400 IU vitarnin D daily throughout the study. Efficacy parameters were the acute and/or pre-dose changes in serum and urinary C-terminal telopeptide of type I collagen (CTx), N-mid osteocalcin (OC), bone-specific alkaline phosphatase (BSALP), calcium, and parathyroid hormone (PTH) measured by established immunoassays. Results: After the first dose, sCT evoked dose-dependent decreases in serum CTx (-60.8% to -81.8% from baseline) compared with placebo, reaching nadirs 2-3 h after drug intake, after which, gradual increases were observed. The simultaneous acute changes in OC were statistically nonsignificant. Area under the curve (AUC) of serum CTx responses at months 1 and 3 showed strong correlation with those at baseline (both r = 0.78, p < 0.001). At month 3. the placebo-corrected changes in the pre-dose value of serum and urinary CTx were significant only in the 1.0-mg dose group (-18.9% and -20.5%, respectively, p < 0.05). The placebo-corrected change in OC was - 8.6 (p = 0.09), whereas the change in BSALP was -7.3 (p = 0.02). The oral formulation was well tolerated, with mild to moderate gastrointestinal and skin manifestations apparent mainly in the high-dose groups. Conclusion: The results of this 3-month trial show that the novel Eligen technology-based oral formulation of sCT has potential to become a safe and effective treatment for postmenopausal bone loss. Future trials are needed to assess the impact of long-term administration on changes in BMD and fracture risk.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Tanko, L. B.
Bagger, Y. Z.
Alexandersen, P.
Devogelaer, J. P.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Chick, R.
Olson, M.
Benmammar, H.
Mindeholm, L.
Azria, M.
Christiansen, C.
Language :
English
Title :
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: Acute and 3-month effects on biomarkers of bone turnover
Publication date :
September 2004
Journal title :
Journal of Bone and Mineral Research
ISSN :
0884-0431
eISSN :
1523-4681
Publisher :
Amer Soc Bone & Mineral Res, Washington, United States - Washington
Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267-276.
Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E 2002 A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: Effects on bone mineral density and bone markers. J Bone Miner Res 17:521-527.
Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, Franchimont P 1994 A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 24:565-569.
Overgaard K, Hansen MA, Jensen SB, Christiansen C 1992 Effect of salmon calcitonin given intra-nasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ 305:556-561.
Overgaard K 1994 Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. Calcif Tissue Int 55:82-86.
Geusens P, Boonen S, Nijs J, Jiang Y, Lowet G, Van Auderkercke R, Huyghe C, Caulin F, Very JM, Dequeker J, Van der Perre G 1986 Effect of salmon calcitonin on femoral bone quality in adult ovariectomized ewes. Calcif Tissue Int 59:315-320.
Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M 1991 Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study. Calcif Tissue Int 49:369-372.
Silverman SL, Azria M 2002 The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13:858-867.
Gennari C, Agnusdei D 1994 Calcitonins and osteoporosis. Br J Clin Pract 48:196-200.
Buclin T, Cosma RM, Burckhardt P, Azria M, Attinger M 2002 Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 17:1478-1485.
Devogelaer JP, Azria M, Attinger M, Abbiati G, Castiglioni C, Nagant de Deuxchaisnes C 1994 Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue. Calcif Tissue Int 55:71-73.
Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C 1998 Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290-2300.
Rosenquist C, Qvist P, Bjarnason N, Christiansen C 1995 Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-1445.
Zikan V, Stepan JJ 2002 Plasma type 1 collagen cross-linked C-telopeptide: A sensitive marker of acute effects of salmon calcitonin on bone resorption. Clin Chim Acta 316:63-69.
Schlemmer A, Ravn P, Hassager C, Christiansen C 1997 Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. Bone 20:63-67.
Thamsborg G, Skousgaard SG, Daugaard H, Schifter S, Kollerup G, Sorensen OH 1993 Acute effects of nasal salmon calcitonin on calcium and bone metabolism. Calcif Tissue Int 53:232-236.
Agnusdei D, Gonnelli S, Camporeale A, Batignani T, Nardi P, Ianes A, Gennari C 1989 Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis. Minerva Endocrinol 14:169-176.
Grigoriou O, Papoulias I, Vitoratos N, Papadias C, Konidaris S, Antoniou G, Chryssikopoulos A 1997 Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study. Maturitas 28:147-151.
Balint-Peric LA, Prelevic GM, Beslagic Z, Petrovic J 1994 The effect of intranasal salmon calcitonin on biochemical parameters of bone turnover in postmenopausal women. Gynecol Endocrinol 8:241-245.
Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M, Lombardi A 1995 Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383-390.
Villa I, Mrak E, Rubinacci A, Guidobono F 2003 Expression of calcitonin and calcitonin - receptor-like receptor in human osteoblast-like cells. Calcif Tissue Int 72:355.
Furuichi H, Fukuyama R, Izumo N, Fujita T, Kohno T, Nakamuta H, Koida M 2000 Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats. Biol Pharm Bull 23:946-951.
Zhang F, Dang G 2001 Effect of sequential application of calcitonin and parathyroid hormone on bone remodeling process, an experimental research. Zhonghua Yi Xue Za Zhi 81:836-840.